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Abstract 
Background 
Effective self-management of diabetes is essential for the reduction of diabetes-related 
complications, as global rates of diabetes escalate. 
Methods 
Randomised controlled trial. Adults with type 2 diabetes (nԜ=Ԝ120), with HbA1c greater than or 
equal to 7.5 %, were randomly allocated (4Ԝ×Ԝ4 block randomised block design) to receive an 
automated, interactive telephone-delivered management intervention or usual routine care. 
Baseline sociodemographic, behavioural and medical history data were collected by self-
administered questionnaires and biological data were obtained during hospital appointments. 
Health-related quality of life (HRQL) was measured using the SF-36. 
Results 
The mean age of participants was 57.4 (SD 8.3), 63 % of whom were male. There were no 
differences in demographic, socioeconomic and behavioural variables between the study 
arms at baseline. Over the six-month period from baseline, participants receiving the 
Australian TLC (Telephone-Linked Care) Diabetes program showed a 0.8 % decrease in 
geometric mean HbA1c from 8.7 % to 7.9 %, compared with a 0.2 % HbA1c reduction (8.9 % 
to 8.7 %) in the usual care arm (pԜ=Ԝ0.002). There was also a significant improvement in 
mental HRQL, with a mean increase of 1.9 in the intervention arm, while the usual care arm 
decreased by 0.8 (pԜ=Ԝ0.007). No significant improvements in physical HRQL were observed. 
Conclusions 
These analyses indicate the efficacy of the Australian TLC Diabetes program with clinically 
significant post-intervention improvements in both glycaemic control and mental HRQL. 
These observed improvements, if supported and maintained by an ongoing program such as 
this, could significantly reduce diabetes-related complications in the longer term. Given the 
accessibility and feasibility of this kind of program, it has strong potential for providing 
effective, ongoing support to many individuals with diabetes in the future. 
Background 
The rapid increase in rates of diabetes poses a significant public health problem globally. 
Diabetes is currently estimated to affect 285 million adults worldwide, with the prevalence 
predicted to rise to 438 million by the year 2030 [1]. Its complications contribute 
significantly to ill health, disability, poor quality of life and premature death. The associated 
global economic burden is projected to reach at least US$376 billion in 2030 [2]. Although 
guidelines and targets for optimal diabetes management are well documented [3], it is 
estimated that 40 % of individuals with diabetes have sub-optimal glycaemic control [4,5], 
significantly increasing their risk of costly and debilitating diabetes-related complications 
[6,7]. 
Diabetes self-management education facilitates the acquisition of knowledge and skills to 
improve disease management and has been found to improve glycaemic control [8], with 
program duration being a critical predictor of this success [9]. Providing ongoing and long-
term diabetes management support, particularly to those people living in rural and remote 
areas, is a major challenge for all health systems around the world. This highlights the need to 
develop and evaluate more feasible, accessible ways of providing such support for large 
numbers of people with diabetes than is traditionally offered. Using information and 
communication technology (ICT) to provide diabetes management education and support 
directly to patients offers such potential, by overcoming many of the barriers associated with 
more traditional modes of program delivery. Use of ICT has been shown to yield 
improvements in self-care knowledge and behaviour of patients and clinical outcomes 
associated with the prevention and control of chronic health conditions, including diabetes 
[10-12]. Some studies have evaluated the role of automated or semi-automated telephone-
delivered diabetes management interventions on glycaemic control, however, the results have 
been inconsistent with varying levels of reliance upon health professionals [13-15]. 
The Telephone-Linked Care (TLC) program is an automated and interactive telephone 
system designed to emulate telephone encounters between patients and health professionals 
[16] and to complement standard medical care. TLC systems have been previously used to 
effectively screen people with specific health conditions [17,18], promote self-care 
behaviours [19-22] and provide monitoring of and feedback to patients with a range of 
chronic diseases [23-26]. 
A randomised controlled trial was conducted to evaluate a TLC program - the Australian 
TLC Diabetes program - designed to improve type 2 diabetes management. This paper 
presents the six-month results for the study’s primary outcomes, glycosylated haemoglobin 
and health-related quality of life (HRQL), and it also describes the sample baseline 
characteristics, compared with a large Australian population study. 
Methods 
Study design 
The study methodology has been detailed elsewhere [27]. In brief, the study was a two-arm 
prospective randomised controlled trial, with adults with type 2 diabetes randomised to either 
the intervention (Australian TLC Diabetes program) arm or ‘usual care’ control arm. Data 
were collected between July 2008 and December 2010. Ethics approval was received from 
the Human Research Ethics Committees for all collaborating hospitals and Monash 
University. 
Participant recruitment and randomisation 
Participants were recruited through advertisements in newspapers, flyers distributed to health 
professionals and to members of Diabetes Australia – Queensland, community newsletters 
and through diabetes clinics at three major hospitals in Brisbane (Princess Alexandra 
Hospital, Royal Brisbane and Women’s Hospital, and Prince Charles Hospital). 
There were two steps to the eligibility screening (Table 1). In the first step, which took place 
during the initial contact via telephone or in person, research staff excluded individuals who 
did not meet all of the Step 1 eligibility criteria or who met any of the Step 1 exclusion 
criteria. If potentially eligible, participants attended a baseline appointment at either Princess 
Alexandra or Royal Brisbane and Women’s Hospital, where full information was provided, 
informed consent was obtained and baseline data collected. At that appointment, baseline 
questionnaires were completed and fasting blood specimens were taken, along with other 
clinical data (blood pressure, weight, height and waist circumference). Blood tests were 
conducted by Queensland Pathology using standardised assays. The second screening step 
verified the glycosylated haemoglobin (HbA1c) inclusion criterion (≥ 7.5 %). The final 
sample included 120 adults; nԜ=Ԝ60 in each of the study arms. The allocation ratio was 1:1 and 
the allocation sequence was computer-generated. The arm allocation was conducted using a 
4x4 block randomised block design with the participant as the unit of randomisation. 
Table 1 Inclusion and exclusion criteria for study recruitment 
Inclusion criteria Exclusion criteria
Eligibility Step 1  
Type 2 diabetes diagnosis ofԜ≥Ԝ3 months Diagnosed with dementia/psychiatric co-morbidity 
Aged 18–70 years 
Residing in greater Brisbane area, 
Australia 
Currently enrolled in another intervention trial 
Stable diabetes pharmacotherapy type 
forԜ≥Ԝ3 months 
Undergone bariatric surgery in past 2 years 
Ability to clearly speak/understand 
English via telephone 
Pregnant, lactating, or planning to become pregnant 
within next 12 months 
Stable pharmacotherapy dosage forԜ≥ 4 
weeks 
Diagnosed with condition likely to be fatal within 1 
year 
Weekly access to telephone  
Eligibility Step 2  
HbA1cԜ≥Ԝ7.5 %  
Study arms 
All participants received a quarterly newsletter containing general health information; this 
aimed to maintain participation in both arms. Participants in both arms were advised to 
continue with their usual medical care. The usual care arm received no further intervention. 
The treating physicians were not blinded to the allocation. 
Intervention arm 
Australian TLC Diabetes program 
The intervention took place over six months during which they received the Australian TLC 
Diabetes program. Its main component is the Telephone-Linked Care (TLC) Diabetes system, 
an automated interactive telephone system, developed collaboratively by the Australian 
research team and researchers at the Medical Information Systems Unit, Boston University, 
USA. The Australian TLC Diabetes system has been designed to improve diabetes 
management by targeting the following key self-management behaviours: blood glucose 
testing, nutrition, physical activity and medication-taking. Users were asked to call the 
system weekly using a landline or mobile phone. TLC’s responses, including feedback and 
encouragement, were tailored according to information entered in the TLC database at the 
start and the answers that it received from participants during all calls. 
Training to use the TLC system 
The TLC Coordinator met with participants within one week of their baseline data collection 
to instruct them on the use of the TLC Diabetes kit (containing the TLC Handbook, an 
ACCU-CHEK® Advantage glucose meter, test strips, and a Bluetooth™ device for 
uploading their blood glucose results to the TLC Diabetes system). For current smokers, a 
smoking cessation information pack was also provided. During this session, participants 
completed a training call to the TLC Diabetes system. Participants were asked to conduct all 
blood glucose self-monitoring with the study glucose meter and to upload its readings 
immediately preceding their weekly telephone conversations with the TLC system. Each 
participant chose a unique personal password that they keyed in at the start of each call that 
linked the call to their database file and ensured correct participant identification and 
confidentiality. Before the participants' first call to the TLC system, the TLC Coordinator 
obtained self-care clinical targets for the participants from their primary healthcare provider 
(including recommended number of weekly blood glucose tests and blood glucose range, and 
clearance for physical activity). 
Content of weekly telephone calls 
Participants were requested to make weekly calls to the system over six months, with calls 
lasting five-20 minutes, depending upon the call content and participant responses. Blood 
glucose monitoring was the first topic covered in each weekly call. It was followed by one of 
three other topics, with these being medication-taking, physical activity or healthy eating 
(calls 9 to 12 and 21 to 24). When diabetes medication was not prescribed, the medication-
taking topic was replaced with physical activity. When clearance for physical activity was not 
provided by the patient’s treating physician, physical activity was replaced by medication-
taking. In cases when there was no clearance for physical activity and no pharmaceutical 
treatment of diabetes, the participant did not hear a second topic on some calls. 
TLC Coordinator 
The TLC Coordinator briefly telephoned participants after the first two calls and at weeks six, 
12, and 20, to identify and resolve any technical issues with the TLC Diabetes system or to 
determine reasons for not calling. In addition, the TLC Diabetes system sent email "alerts" to 
a dedicated study email address if any unusual clinical or other issues arose during the 
conversations, for example, where there were two or more hypoglycaemic levels in the past 
week. In this instance, the Coordinator would advise the participant of the importance of 
visiting their primary care physician. More detail on the intervention is available elsewhere 
[27]. 
Measurement 
Participants in both arms completed comprehensive clinical and self-report assessments at 
baseline (Time 1), six months following baseline (Time 2), and at 12 months (Time 3); this 
paper presents the baseline characteristics and six-month primary outcome findings. 
Outcome variables 
The primary outcomes were HbA1c measured by fasting blood tests taken at the hospital 
appointment, and HRQL assessed by the participants’ self-completion of the SF-36 version 2 
(divided into mental and physical component summary scores) [28]. 
Figure 1 illustrates the stages of recruitment and randomisation. 
Figure 1 Participant flow diagram 
Representativeness of study sample (Table 2) 
Table 2 Baseline characteristics of Australian Telephone-Linked Care (TLC) Diabetes 
sample 
 TLC Diabetes 
Intervention 
(nԜ=Ԝ60) 
Usual care 
(n = 60) 
Total TLC 
sample 
(n = 120) 
AusDiab sub-
sample 
(nԜ=Ԝ156) 
Demographic variables     
Age 58.4 (8.2) 56.4 (8.3) 57.4 (8.3) 56.6 (8.8) 
Sex - % male 61.7 63.3 62.5 59.8 
Country of birth – % born in 
Australia 
71.7 68.3 70.0 66.7 
Marital status – % cohabiting 75.4 74.6 75.0 67.9 
Employment – % working 46.7 45.0 45.8 47.7 
Income – %Ԝ>Ԝ$40,000 46.7 51.7 49.2  
Education – %Ԝ>Ԝsecondary 
school 
60 70 65.0 55.8 
Private medical insurance –% 
with 
56.7 55.0 55.8 47.3 
Psychosocial risk factors –     
Depression–Low 66.7 78.3 72.5 - 
Intermediate 26.7 20.0 23.3  
High 6.7 1.7 4.2  
Anxiety – Low 90.0 88.3 89.2 - 
Intermediate 6.7 8.3 7.5  
High 3.3 3.3 3.3  
Social support – % low 20.0 21.7 20.8 NC 
Nutritional self-efficacy 15.2 (3.0) 15.0 (3.2) 15.1 (3.1) NC 
Physical activity self-efficacy 12.8 (3.3) 12.7 (3.5) 12.7 (3.4) NC 
HRQL – Physical component 
summary 
43.7 (8.4) 43.8 (10.2) 43.6 (9.3) 45.2 (12.7) 
Mental component summary 49.8 (8.7) 49.5 (9.1) 49.6 (8.9) 49.5 (9.8) 
Health behaviours     
Smoking status – % never 51.7 53.3 52.5 34.0 
% ex-smoker 45.0 46.7 45.0 45.5 
% current 3.3 0 1.7 17.9* 
Physical activity – % none 5.0 5.2 5.1 22.4 
% do not meet guidelines 35.0 43.1 39.0 31.4 
% meet guidelines 60.0 51.7 55.9 46.2* 
Diet (nԜ=Ԝ110) – Energy 
(kJ/day) ‡ 
7658 (5884–9745) 7811 
(6080–
9566) 
7704 (6025–
9638) 
7467 (5850–
9455) 
Fibre (g/day) ‡ 23 (18–29) 23 (17–29) 23 (17–29) 23 (17–30) 
Fat (g/day) ‡ 73 (53–93) 76 (63–95) 75 (57–94) 71 (56–94) 
Saturated fat (g/day) ‡ 27 (21–37) 30 (23–38) 29 (22–38) 28 (22–38) 
Self-care –     
% adherence to blood glucose 
testing 
    
recommendations 40.0 30.0 36.2 NC 
% checked feet everyday 31.7 20.0 26.1 NC 
% insulin/diabetes medical 
adherence everyday 
87.9 86.0 84.0 NC 
Self-reported health – 
%Ԝ≥Ԝgood 
74.9 73.3 74.2 65.8 
Medication use     
Inject insulin – % on insulin 41.7 45.0 43.3 NC 
Clinical measures     
Systolic blood pressure 
(mmHg) 
135.4 (15.0) 137.0 
(15.0) 
136.2 (15.0) 140.2 (18.9)* 
Diastolic blood pressure 
(mmHg) 
80.6 (9.6) 81.1 (10.0) 80.9 (9.7) 75.7 (12.0)* 
Body mass index (kg/m2) ‡ 32.5 (28.7-35.9) 32.9 (29.2-
37.8) 
33.6 (28.8-
36.9) 
30.0 (26.5-
34.6)* 
Waist circumference (cm) ‡ 107.7 (100.0-114.6) 113.1 
(101.7-
122.4) 
111.0 (101.5-
118.7) 
103.2 (92.0-
115.2)* 
Glycosylated haemoglobin 
(HbA1c) (%)‡ 
8.6 (8.0-9.2) 8.5 (7.9-
9.5) 
8.5 (7.9-9.3) 8.8 (8.1-9.8)* 
Fasting glucose (mmol/l) ‡ 9.8 (8.4-11.1) 9.5 (8.1-
12.0) 
9.6 (8.2-11.4) 11.5 (9.8-
14.1)* 
Fasting insulin (mU/l) ‡ 15.0 (9.6-24.0) 13.0 (8.3-
22.8) 
14.0 (9.1-
23.8) 
NC 
HOMA Insulin Resistance ‡ 2.3 (1.4-3.6) 1.9 (1.2-
3.0) 
2.2 (1.3-3.3) NC 
Total cholesterol (mmol/l) ‡ 4.0 (3.5-4.9) 4.0 (3.4-
5.2) 
4.0 (3.5-5.2) 5.6 (4.8-6.3) * 
High density lipoprotein 
cholesterol (mmol/l) ‡ 
1.0 (0.8-1.1) 1.0 (0.8-
1.2) 
1.0 (0.8-1.1) 1.2 (1.0-1.4) * 
Low density lipoprotein 
cholesterol (mmol/l) ‡ 
2.1 (1.8-3.1) 2.2 (1.6-
3.0) 
2.1 (1.7-3.0) 3.2 (2.7-3.9)* 
Triglycerides (mmol/l) ‡ 1.6 (1–2.1) 1.5 (1.1-
2.0) 
1.5 (1.1-2.1) 2.0 (1.3-2.9) * 
Creatinine (μmol) ‡ 83.0 (64.8-98.5) 73.0 (62.0-
86.8) 
78.0 (62.8-
95.3) 
83.5 (73.0-
92.8)* 
Estimated glomerular 
filtration rate (ml/min) ‡ † 
76.0 (64.0-91.0) 85.5 (77.3-
91.0)* 
83.0 (70.8-
91.0) 
78.1 (69.5-
87.7)* 
Clinical history (self-report)     
Doctor-diagnosed 
hypertension (%) 
63.3 68.3 65.8 46.8 
Doctor-diagnosed 
hypercholesterolaemia (%) 
60.0 66.7 63.3 48.0 
Doctor-diagnosed diabetic 
eye complications (%) 
15.0 21.7 18.3 NC 
Doctor-diagnosed diabetic 
neuropathy (%) 
18.3 25.0 21.7 NC 
Doctor-diagnosed kidney 
disease (%) 
11.7 5.0 8.3 NC 
Doctor-diagnosed 
cardiovascular disease (%) 
28.3 30.0 29.2 NC 
Data are presented as means (SD) and percentages, or as ‡medians (inter-quartile range) for 
skewed data. Group comparisons between TLC study arms and between TLC and AusDiab 
samples of normally distributed data used independent samples t-tests and chi square tests. 
Group comparisons between TLC study arms and between TLC and AusDiab samples of 
non-normally distributed variables used Mann–Whitney U test, *p <0.05. 
† Estimated glomerular filtration rate data highly skewed (values over 90 ml/min labelled 91). 
HRQL: Health-related quality of life. 
HOMA: Homeostasis model assessment. 
High risk AusDiab group inclusion criteria are type 2 diabetes, within TLC age-range, and 
HbA1cԜ≥Ԝ7.5 %; TLC-AusDiab group comparison are made with full TLC sample (nԜ=Ԝ120). 
NC: Not comparable - missing comparisons with AusDiab subsample due to incomparable 
methods of data collection between studies. 
To examine the representativeness of the Australian TLC Diabetes sample, the baseline 
characteristics were compared with data from the Australian Diabetes, Obesity and Lifestyle 
(AusDiab) study [29], the largest national, population-based sample of Australians measuring 
the overall prevalence of diabetes and other chronic conditions. The AusDiab baseline study 
was conducted during 1999–2000 with data from 11,247 adults [29]. Demographic and 
behavioural data were collected during interview, and diabetes status was assessed using 
fasting plasma glucose and oral glucose tolerance tests. A subsample of this nationally 
representative study, those identified as having diabetes (and based on TLC inclusion 
criteria), provides the best comparison for the TLC study sample. 
Statistical analyses 
Detailed power calculations were described in an earlier paper [27], indicating the need to 
recruit 340 participants to detect a small clinical change of 0.4 % in HbA1c with 90 % power 
assuming a 30 % rate of loss to follow-up. However, due to the slowness of recruitment 
(described below), our final sample comprised a total of 120 participants (60 per study arm). 
Although the comprehensive recruitment effort achieved a very good response from 
individuals with diabetes (nԜ=Ԝ512), a large proportion of these respondents either did not wish 
to participate or were ineligible due to either not meeting the HbA1c or age eligibility criteria. 
Recruitment was stopped after 18 months with 120 participants having been recruited. 
Therefore, the power calculations were re-evaluated based on this number of participants, 
again assuming 30 % loss to follow-up. With 80 % power and a type 1 error of 5 % (two-
tailed), a difference in our primary outcome, HbA1c, of 0.61 % between the intervention and 
control arms (based on a standard deviation change of 1.0 % between the randomised arms) 
at 12-month follow-up can be detected. This effect size would indicate a feasible outcome of 
clinical significance [30] for the intervention. 
For the analysis of the six-month results, HbA1c values were logarithmically transformed in 
order to achieve an approximate normal distribution. Analyses of covariance were used to 
examine the effects of the intervention (study arm allocation) on the primary outcomes (log 
HbA1c and HRQL), with the inclusion of baseline values of the outcomes as covariates. 
Results for HbA1c are presented as geometric means for each study arm and as a ratio of 
geometric means when comparing study arms. The geometric mean is a natural quantity to 
use for presenting the centre of skewed data and is computed by exponentiating the average 
of the logarithmically transformed HbA1c values [31]. To assess heterogeneity of the effect of 
TLC according to baseline values, interactions between study arm allocation and baseline 
values were included in further regression models. Creatinine and e-GFR were included as 
covariates in these analyses, since their levels at baseline differed sizeably between study 
arms. The sensitivity of conclusions to imbalances in baseline characteristics was assessed 
via additional ANCOVA analyses adjusting for all characteristics exhibiting any potentially 
important imbalances. To account for subjects lost to follow-up in intention-to-treat analyses, 
multiple imputation was performed using ten imputed datasets [32]. 
For the comparison of the baseline TLC sample characteristics with the AusDiab study 
sample, as well as for the attrition comparisons, independent samples t-tests (continuous data) 
and chi-square tests (categorical data) were used where the data were normally distributed, 
and Mann–Whitney U tests were employed for highly skewed data. All analyses were 
performed using SPSS 18.0, with the statistical significance level set at pԜ<Ԝ0.05. 
Results 
Of the 52 individuals who did not wish to participate at the initial eligibility screening stage, 
the primary reason for non-participation was lack of interest (nԜ=Ԝ21), with an additional 11 
reporting potential difficulties with travel for the baseline data collection. Other reasons 
included lack of time due to work and other commitments. There were no age differences 
between those who were willing and unwilling to participate, although there was a higher 
proportion of women who were unwilling to participate compared with those who chose to 
participate (61.5 % compared with 43 %). 
As shown in Table 2, which summarizes the baseline characteristics of the TLC and usual 
care arms, the Australian TLC Diabetes sample had a mean age of 57.4 years (± 8.3), with a 
higher proportion of men (62.5 %) than women. The vast majority of participants were born 
in Australia (70.0 %), were married or cohabiting with a partner (75.0 %), with education 
above secondary school level (65.0 %). Approximately half of the sample were employed 
(45.8 %) and had complementary private medical insurance (55.8 %). The mean number of 
hours per week spent exercising was reported to be 6.1 (± 6.4), with the majority of the 
sample (55.9 %) participating in the nationally-recommended level of weekly physical 
activity (>150 minutes of exercise per week in at least 5 sessions per week [33]). Only 1.7 % 
of the sample were current smokers. Approximately three quarters of the sample rated their 
health as good or higher (74.2 %). Nearly two-thirds of the sample had been previously 
diagnosed by a doctor with hypertension (65.8 %) and hypercholesterolaemia (63.3 %), and 
therefore were likely to be receiving treatment for these conditions as was reflected in their 
blood pressure and lipid profiles that predominantly fell within the normal range. 
Comparison of baseline sample characteristics between study arms 
The baseline sample characteristics were compared across the usual care and intervention 
arms to evaluate the randomisation process (Table 2). Comparison of the baseline 
characteristics across usual care and intervention arms revealed important differences in e-
GFR, which showed a significantly greater impairment in renal function in the intervention 
compared with usual care arm, and creatinine. Other differences observed were in age, 
education, and self-care behaviours (adherence to blood glucose testing recommendations 
and daily insulin/diabetes medications, and foot inspections). Adjustments were made for 
these variables in sensitivity analyses. 
Post-intervention results at six months 
Attrition 
Of the total sample, 92.5 % completed the six-month assessment (see Figure 1). Overall, nine 
participants (two women and seven men) withdrew from participation in the study, four in the 
intervention arm and five in the usual care arm. The reasons given for withdrawal from the 
usual care arm were all related to frustration at ‘missing out’ on the intervention. The 
participants receiving the Australian TLC Diabetes intervention withdrew for a range of 
reasons, including relocation, being unable to use the blood glucose meter, and 
disappointment with the intervention. The sociodemographic, behavioural or biological 
profiles were compared between those people who remained in the study and the nine people 
who withdrew. There were no significant differences at baseline across any of the domains of 
risk factor profiles. 
Use of Australian TLC Diabetes system 
The mean number of completed calls for the Australian TLC Diabetes participants during the 
six-month intervention was 18 (± 6), ranging between 2 and 27 calls, with a mean call 
duration of 11 minutes (± 1). The mean percentage of completed calls out of the expected 
weekly calls for all individuals in the intervention condition was 76 % (± 22). More detailed 
analyses of the usage of the Australian TLC Diabetes system are beyond the scope of this 
paper and are to be presented in a future manuscript. 
A small number of people in the intervention arm (nԜ=Ԝ5) discontinued participation in the 
intervention but still completed the six-month assessment (Figure 1). Out of these, two 
participants made less than five calls and one made only seven calls. 
Study outcomes 
These analyses were based on intention-to-treat. There was a statistically significant 
difference in HbA1c at six months between the usual care and TLC Diabetes arms. The 
geometric mean (arithmetic means provided in parentheses) of HbA1c decreased from 8.7 % 
(8.8 %) to 7.9 % (8.0 %) in the TLC Diabetes arm, compared with 8.9 % (9.0 %) to 8.7 % 
(8.9 %) in the usual care arm, with the adjusted ratio of six-month geometric means of 0.91 
(95 % CI 0.86-0.93, pԜ=Ԝ0.002) (Table 3). The ratio of 0.91 means that the geometric mean 
HbA1c at six months in the TLC arm is 0.91 of the value in the usual care arm after 
adjustment for baseline covariates. There was slight evidence that the difference in HbA1c at 
six months between study arms increased with baseline HbA1c (pԜ=Ԝ0.09 for the interaction 
term in regression model). This suggested that the difference in six-month HbA1c between 
TLC and usual care patients was greater in patients with high baseline HbA1c values than in 
patients with low values. Of participants in the intervention arm, 20 % achieved HbA1c levels 
of 7.0 % or lower (95 % CI 9.6-29.7), compared with 15 % (95 % CI 4.4-24.7) in the usual 
care arm (pԜ=Ԝ0.32). 
Table 3 Baseline and post-intervention primary outcome values between usual care and 
Australian TLC Diabetes arms 
 Baseline 
nԜ=Ԝ60 
Post-intervention 
n = 60 
Difference between groups* 
(95 % CI, p) 
HbA1c (%)   Ratio 
Usual care 8.9 (8.6-9.2) 8.7 (8.7-9.0) 0.91 (0.86-0.93, pԜ=Ԝ0.002) 
TLC Diabetes 8.7 (8.4-9.0) 7.9 (7.6-8.3)  
Health-related quality of 
life - mental 
   
Usual care 49.5 (47.1-
50.3) 
48.7 (47.1-50.3) 3.0 (0.8-5.2 pԜ=Ԝ0.007) 
TLC Diabetes 49.8 (47.5-
52.0) 
51.7 (50.2-53.3)  
Health-related quality of 
life - physical 
   
Usual care 45.4 (43.0-
47.9) 
45.2 (43.8-46.6) 0.4 (−1.7-2.4, pԜ=Ԝ0.7) 
TLC Diabetes 45.5 (43.0-
47.9) 
45.6 (44.1-47.0)  
Data presented in the first two columns are geometric means (95 % CI) for HbA1c values and 
arithmetic means (95 % CI) for HRQL values. The post-intervention values are adjusted for 
baseline values, e-GFR and creatinine. 
*The result in the last column for HbA1c is the ratio of the geometric means in the TLC 
Diabetes arm compared with usual care arm. 
For HRQL, it is the difference in arithmetic means. All analyses were conducted based on the 
intention-to-treat principle and adjust for the baseline of the outcome variable, e-GFR and 
creatinine values. 
In terms of HRQL, the mental component summary score was found to be significantly 
different between the two arms at six months (differenceԜ=Ԝ3.0, pԜ=Ԝ0.007), after controlling 
for baseline mental HRQL, plus other covariates (Table 3). Mental HRQL improved in the 
TLC Diabetes group, compared with those in the usual care group where mental HRQL 
decreased marginally. There was no interaction between study arm allocation and baseline 
levels for mental HRQL (pԜ=Ԝ0.4). No differences were observed in physical HRQL between 
the usual care and intervention arms (pԜ=Ԝ0.7). 
Comparison of sample characteristics between Australian TLC and AusDiab 
samples 
To determine the representativeness of the TLC sample at baseline, we used a comparable 
subsample of individuals from the AusDiab study, obtained from applying the Australian 
TLC Diabetes criteria for age range and HbA1c levels (≥ 7.5 %) to the subsample (nԜ=Ԝ643) of 
those classified in AusDiab as having diabetes. 156 AusDiab participants were identified for 
comparison with the Australian TLC Diabetes sample. Overall, the AusDiab and TLC 
samples were similar (Table 2). There were no significant differences between the TLC 
sample and the AusDiab subsample across demographic variables, HRQL, and self-reported 
health variables. Behaviourally, there were no differences in nutrition self-reports between 
the study populations, however the TLC sample reported markedly lower smoking rates and 
were more likely to perform the recommended levels of exercise. In terms of their clinical 
profiles, the TLC sample appeared healthier, with lower systolic blood pressure, and 
generally better glucose and lipid profiles. These results, however, are likely to reflect the 
increased levels of doctor-diagnosed hypertension and hypercholesterolaemia, and therefore 
probably high levels of treatment in the TLC sample. Interestingly, despite their reported 
healthier behavioural profiles, the TLC sample were significantly more likely to be obese 
using both BMI and waist circumference classifications. 
Discussion 
This randomised controlled trial evaluated the efficacy of an automated, interactive telephone 
intervention for improving the management of diabetes. As far as we are aware, this is one of 
the first studies in the world to formally evaluate an automated telephone system for diabetes 
management that involves tailoring to individual needs and the findings offer promising 
results for the longer term use of this kind of program for people with diabetes. We have 
demonstrated that the Australian TLC Diabetes program significantly improved glycaemic 
control and mental HRQL after six months for those who participated in the program 
compared with the routine care condition. 
Participation in the Australian TLC Diabetes intervention led to a significant improvement of 
HbA1c, compared with the routine care available to people with diabetes in Brisbane, 
Australia. The mean reduction in HbA1c of 0.8 % in the intervention arm is of substantial 
clinical significance if maintained long-term. Results from the UKPDS study highlight the 
substantial reductions in all diabetes endpoints associated with 1 % reduction in HbA1c [7], 
such as 21 % of deaths related to diabetes, 14 % of myocardial infarction and 37 % 
microvascular complications [30]. A meta-analysis reported comparable levels of HbA1c 
improvement from the pooled effects of 31 previous interventions providing education on 
self-management of diabetes [9]. The majority of studies cited in the review, however, 
directly involved healthcare professionals/health workers for the provision of diabetes 
management education. Another meta-analysis evaluating the use of mobile phone 
interventions to improve glycaemic control showed a pooled change of 0.5 % over six 
months, however, again with heavy involvement of healthcare personnel for intervention 
delivery [11]. One previous study of another fully-automated telephone intervention aimed at 
improving glycaemic control failed to show significant post-intervention differences between 
intervention and control groups in levels of HbA1c [13]; however, that system did not provide 
tailored feedback to individuals. Therefore, a major advantage of the Australian TLC 
Diabetes program is its successful impact on glycaemic control and the potential for reduced 
costs and increased accessibility associated with an automated telephone-linked system for 
the provision of tailored diabetes management. 
In addition to the observed improvements in glycaemic control, mental HRQL was 
significantly enhanced in people who received the intervention compared with those who did 
not, despite this not being a specific focus of the TLC program for the trial. The burden of 
daily management of diabetes and the development of complications lead to compromised 
HRQL in populations with diabetes [34,35], and therefore enhancing well-being, in addition 
to diabetes management per se, is an additionally important outcome. Despite this 
improvement reflecting only a small effect size (0.20) [36], the literature in this field 
indicates that even small effect sizes of HRQL improvement may be of clinical significance 
in the longer term [37-39]. Interestingly, the physical component of HRQL did not improve 
during the six-month intervention period. A brief computer-assisted diabetes self-
management intervention on quality of life outcomes showed no change in HRQL, however, 
their two-month follow-up might not have been long enough to detect changes [40]. In 
contrast, the pooled results from 20 publications showed that people with diabetes experience 
improved HRQL after receiving interventions designed to develop their diabetes self-
management behaviours [37], although this meta-analysis did not differentiate between the 
mental and physical components of HRQL. 
Another important aspect of this study is the focus on people with poor glycaemic control 
(HbA1cԜ≥Ԝ7.5 %), indicating difficulty in their self-management of diabetes with the available 
routine care. These people are likely to be most at risk of the development of complications 
associated with diabetes, and therefore, given the results achieved, Australian TLC Diabetes 
has the potential to improve the health of the highest risk groups. Consequently, this program 
also provides the opportunity to significantly reduce the financial burden of type 2 diabetes 
on the healthcare system. Subsequent analyses will examine the cost-effectiveness of the 
program, which will have important implications for the widespread implementation of the 
program. 
Our comparison of the TLC sample with a ‘matched’ subgroup from the AusDiab study 
sample suggests that the TLC participants did not differ significantly in terms of demographic 
characteristics from the best available data from a general population-based diabetes sample 
in Australia. The baseline AusDiab study, conducted in 1999–2000, offers benchmark 
national data on the prevalence of diabetes, obesity, hypertension, and kidney disease in 
Australia. This indicates the representativeness and external validity of our results and their 
applicability to other diabetes populations. 
The trial was completed in accordance with the Medical Research Council’s guidelines for 
the effective design and evaluation of complex intervention trials [41]. Principal components 
of any effective complex intervention include feasibility, participant-engagement, 
identification of mechanisms for intervention outcomes, and trial fidelity [42]. The feasibility 
and relevance of the Australian TLC Diabetes program are demonstrable within the current 
context of type 2 diabetes. The accessibility of the telephone-delivered intervention over the 
long-term is particularly important for a widespread chronic condition, such as diabetes, 
which requires ongoing management and affects a large proportion of the population. The 
very high usage of the Australian TLC Diabetes system and results to date indicate that the 
participants in the intervention arm engaged with the program, with over three quarters of 
weekly calls being completed. Full details of system usage were recorded as part of the data 
collection and will be reported elsewhere for full process evaluation of the system’s usability 
and participant satisfaction, as well as whether the cost of the intervention provides 
acceptable value for money. Furthermore, the intervention was able to affect pathways that 
led to improvements in glycosylated haemoglobin and therefore diabetes management, as 
well as improvement in mental health-related quality of life for the participants. The fidelity 
of the trial implementation in accordance with the original design and protocol [27] was 
strong. Difficulties were encountered during recruitment and this led to increased recruitment 
opportunities via enhanced presence at Diabetes Australia – Queensland shops and seminars 
and hospital diabetes clinics. The sample size was smaller than originally planned, however, 
as discussed, the sample obtained is powered to detect group differences that will be both 
statistically and clinically significant at 12-month follow-up. No changes were applied 
regarding the randomisation process or implementation of the intervention. 
Although only glomerular filtration rate significantly varied across the study arms at baseline, 
other baseline characteristics (Table 2) showed some differences. Separate analyses tested the 
impact of the inclusion of these variables individually on the main results and the main 
outcome results did not change. As with most research, it is possible that a selection bias 
operated in this study, with people willing to participate being more likely to prioritise their 
health and/or have the social, educational, and economic resources to accommodate 
participation. The study requirement of access to a telephone meant that there may have been 
a socioeconomic selection bias; however in the geographic area from which we recruited, 
over 96 % of households have a fixed phone connection, so we are confident that this 
criterion did not appreciably influence participation. It is also possible that the reduced 
sample size and some of the challenges associated with trial recruitment may limit 
generalisability. More research is required to investigate generalizability and to explore 
uptake by others with diabetes. Although there was a suggestion of an increasing effect of 
intervention with increasing baseline HbA1c values (from the interaction test), this did not 
reach conventional levels of statistical significance and should be reassessed in future studies. 
A substantial body of research conducted over the last 30 years has drawn attention to the 
importance of ongoing support and follow-up to sustain improvements in diabetes 
management and management of other chronic conditions, with strong links to health and 
self-care behaviours [43-45]. Therefore a diabetes management support program such as this, 
designed to provide easy access to long-term (potentially cost-effective) support, is of 
paramount importance, and hence, this kind of program also requires detailed evaluation in 
the longer term as well. A subsequent paper will elucidate the changes in behaviour that may 
have facilitated the improvements observed. 
Conclusions 
Our results indicate that the six-month Australian TLC Diabetes program led to 
improvements in diabetes management, with significant benefits to mental health functioning 
and improved glycaemic control. If these results were maintained long term, such results 
would be expected to lead to important reductions in diabetes-related complications and 
mortality [30]. With the increasing accessibility to and feasibility of such telehealth 
interventions, the TLC program has excellent potential to be ‘scaled up’ and deliverable to 
large numbers of individuals with diabetes. 
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